Tango Therapeutics, Inc. (TNGX) News
Follow Tango Therapeutics, Inc. (TNGX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Tango Therapeutics reports Q3 basic EPS loss
Tango Therapeutics reported Q3 operating expenses of USD 78.116 million.
EQUITY | Nov 09, 2026, 12:23 PM UTC
M
Tango Therapeutics Q3'26 Results Scheduled for November 10
Tango Therapeutics is scheduled to report Q3'26 results on November 10; the report is expected at 7:00 a.m. ET. EPS is anticipated at $(0.35).
EQUITY | Nov 03, 2026, 12:00 PM UTC
M
Tango Therapeutics Shares Fall 14% After Pancreatic Cancer Study Results
An ongoing study found vopimetostat was not well tolerated at a certain dose level. Tango Therapeutics shares fell 14% to $24.13 on Friday.
EQUITY | Oct 23, 2026, 04:36 PM UTC
M
Tango Therapeutics Reports 82% ORR in 2L/3L PDAC Patients
Tango Therapeutics reported an 88% 9-month PFS rate among 22 efficacy-evaluable patients treated with vopimetostat plus daraxonrasib; median PFS was not yet reached. The company expects a registrational front-line Phase
EARNINGS | Oct 23, 2026, 10:36 AM UTC
L
TNGX: Vopimetostat delivers breakthrough efficacy in cancer, with pivotal data and regulatory updates ahead
Vopimetostat, a PRMT5 inhibitor, has shown unprecedented response rates in pancreatic cancer and is advancing toward regulatory approval, with a strong focus on combination therapies and expansion into lung cancer and gl
EQUITY | Sep 09, 2026, 02:14 PM UTC
M
TNGX’s vopimetostat PRMT5 inhibitor expands into lung and brain tumors
TNGX said vopimetostat, a PRMT5 inhibitor, is advancing toward approval and expanding beyond pancreatic cancer into lung cancer and glioblastoma, with additional data updates expected at ESMO.
EQUITY | Sep 09, 2026, 01:42 PM UTC
L
Tango Therapeutics announces Nasdaq Rule 5635(c)(4) inducement grants
Tango Therapeutics (TNGX) announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Tango Therapeutics grants 146,500-share non-qualified stock option
Tango Therapeutics said its Compensation Committee granted a non-qualified stock option to purchase 146,500 shares, effective September 1, 2026.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Tango Therapeutics management set for Cantor Global Healthcare fireside chat Sept. 9
Tango Therapeutics (TNGX) said members of its management team are scheduled for a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026.
EQUITY | Sep 01, 2026, 11:07 AM UTC
L
TNGX - Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TNGX - Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
EQUITY | Sep 01, 2026, 11:00 AM UTC
M
TNGX Files Prospectus For $400M Common Stock
Tango Therapeutics files prospectus for up to $400M common stock offering
EQUITY | Aug 11, 2026, 09:14 PM UTC
L
TNGX PT raised from $36 to $40, maintains Outperform @ Mizuho
TNGX PT raised from $36 to $40, maintains Outperform @ Mizuho
EQUITY | Jul 17, 2026, 11:25 AM UTC
L
TNGX Initiated Overweight W/$46.00 PT at JPMorgan
TNGX Initiated Overweight W/$46.00 PT at JPMorgan
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
TNGX new Overweight W/ $46 PT @ JPMC
TNGX new Overweight W/ $46 PT @ JPMC
EQUITY | Jul 15, 2026, 11:22 AM UTC